Sera Prognostics, Inc. (SERA) stock
Close on Nov 11, 2026Market cap $76.53MP/E –Yield –
Sera Prognostics, Inc. grew revenue 1.1% to $96.00K over the twelve months to Sep 30, 2026. Free cash flow was -$28.99M. At the latest close the market valued the company at $76.53M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $76.53M
- P/E ratio
- –
- Price to sales
- 797.21
- Price to book
- 1.46
- Dividend yield
- –
- Free cash flow yield
- -37.88%
Fundamentals
- Revenue
- $96.00K
- Net income
- -$33.47M
- EPS, diluted
- -$0.67
- Free cash flow
- -$28.99M
- Book value per share
- $1.03
- Diluted shares
- 51M
Trading
- Next earnings
- Mar 17, 2027 (estimated, after the close)
- Previous close
- $1.99
- Open
- $2.05
- Day's range
- $1.91 – $2.05
- Volume
- 84,546
- Average volume (20 days)
- 40,988
- Beta (5 years)
- 1.23
- 52-week range
- $1.56 – $3.85
- RSI (14 days)
- 42.1
- Volatility (1 year)
- 69.0%
- Relative volume
- 2.91×
- WACC
- 11.0%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SERA | S&P 500 | Difference | SERA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.9% | -2.4% | −2.5 pts | ||
| 3 months | -2.5% | -1.2% | −1.4 pts | ||
| Year to date | -34.2% | +12.3% | −46.5 pts | ||
| 1 year | -27.9% | +12.4% | −40.3 pts | ||
| 3 years | +14.8% | +78.8% | −64.0 pts | +4.7% | +21.4% |
| 5 years | -82.3% | +75.2% | −157.4 pts | -29.3% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sera Prognostics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Update
About Sera Prognostics
Services-Medical Laboratories
Sera Prognostics is a women’s health diagnostics company focused on improving maternal and neonatal outcomes through biomarker discovery. The company combines proteomics and bioinformatics platforms with clinical data to develop blood-based tests and predictive analytic tools. Its primary commercial product is the PreTRM test, a non-invasive blood test administered during weeks 18 through 20 of pregnancy to evaluate the risk of spontaneous preterm birth in women carrying a single fetus. The company's technology platform identifies dynamic protein changes to detect adverse pregnancy conditions.
Company profile, executives and historySera Prognostics stock: common questions
What is Sera Prognostics's stock price?
SERA closed at $1.94 on Nov 11, 2026, down 2.51% on the day. Over the past 52 weeks it traded between $1.56 and $3.85.
What is Sera Prognostics's market cap?
Sera Prognostics was worth $76.53M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SERA's P/E ratio?
Sera Prognostics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.67), so it has no meaningful P/E ratio.
How much revenue does Sera Prognostics make?
Sera Prognostics reported revenue of $96.00K for the twelve months to Sep 30, 2026, up 1.1% from a year earlier.
Does Sera Prognostics pay a dividend?
No. Sera Prognostics has not paid a cash dividend over the last twelve months.
When does Sera Prognostics report earnings next?
Sera Prognostics is expected to report Q4 FY2026 results on Mar 17, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SERA stock performed over the past year?
Including dividends, SERA returned -27.9% over the past year, against +12.4% for the S&P 500.
How many SERA shares are sold short?
0M shares were sold short at the latest FINRA report, 0.80% of the float, or 9.1 days of average trading volume.
Who are Sera Prognostics's competitors?
Companies most similar to Sera Prognostics by business, industry and size include ADVB, ACON, YDES, AWHL, BGLC.
See a number that looks wrong?